학술논문
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
Document Type
Article
Author
Source
In: BMJ open . (BMJ open, 3 March 2022, 12(3):e055821)
Subject
Language
English
ISSN
20446055